Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Schiffman

Showing results (181-190 of 187) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 187 results.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)|April 2, 2025
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia ProgramMichael P Harms, Kang-Ik K Cho, Alan Anticevic, et al.
Schizophrenia (Heidelberg, Germany)|March 25, 2025
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sampleKelly Allott, Walid Yassin, Luis Alameda, et al.
Schizophrenia (Heidelberg, Germany)|June 6, 2025
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measuresDaniel H Mathalon, Spero Nicholas, Brian J Roach, et al.
Molecular Psychiatry|October 22, 2025
Structural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR StudySiwei Liu, Ingrid Agartz, Paul Allen, et al.
JAMA Psychiatry|May 5, 2021
Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis: An ENIGMA Working Group Mega-analysis, Maria Jalbrzikowski, Rebecca A Hayes, et al.
Schizophrenia Bulletin|March 7, 2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for PsychosisCassandra M J Wannan, Barnaby Nelson, Jean Addington, et al.
Pageof 19

Showing results (181-190 of 187) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 187 results.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)|April 2, 2025
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia ProgramMichael P Harms, Kang-Ik K Cho, Alan Anticevic, et al.
Schizophrenia (Heidelberg, Germany)|March 25, 2025
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sampleKelly Allott, Walid Yassin, Luis Alameda, et al.
Schizophrenia (Heidelberg, Germany)|June 6, 2025
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measuresDaniel H Mathalon, Spero Nicholas, Brian J Roach, et al.
Molecular Psychiatry|October 22, 2025
Structural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR StudySiwei Liu, Ingrid Agartz, Paul Allen, et al.
JAMA Psychiatry|May 5, 2021
Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis: An ENIGMA Working Group Mega-analysis, Maria Jalbrzikowski, Rebecca A Hayes, et al.
Schizophrenia Bulletin|March 7, 2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for PsychosisCassandra M J Wannan, Barnaby Nelson, Jean Addington, et al.
Pageof 19